TARA Insider Trading
Insider Ownership Percentage: 12.50%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $987,261.16
Protara Therapeutics Insider Trading History Chart
This chart shows the insider buying and selling history at Protara Therapeutics by year and by quarter.
Skip ChartChart Data in Insider Trading History Table
Protara Therapeutics Share Price & Price History
Current Price: $3.91
Price Change: ▲ Price Increase of +0.16 (4.27%)
As of 04/11/2025 05:00 PM ET
Protara Therapeutics Insider Trading History
Protara Therapeutics Institutional Trading History
Data available starting January 2016
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.
Read More on Protara Therapeutics
Volume
220,891 shs
Average Volume
762,496 shs
Market Capitalization
$143.76 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.6
Who are the company insiders with the largest holdings of Protara Therapeutics?